Journal
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY
Volume 26, Issue 6, Pages 803-818Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.bpg.2012.12.004
Keywords
Neuroendocrine tumour NET; Computed tomography CT; Magnetic resonance imaging MRI; Scintigraphy; SPECT; OctreoScan; Positron emission tomography PET; Ultrasound US; Endoscopic ultrasound EUS; 68Ga; 68Ga-DOTATOC; 11C-5-hydroxytryptophan; FDOPA
Categories
Ask authors/readers for more resources
Neuroendocrine tumours (NETS) comprise a heterogeneous group of neoplasms with very varying clinical expression. A functioning NET, for instance in the pancreas, may be very small and yet give rise to severe endocrine symptoms whereas a patient with a small bowel tumour may present with diffuse symptoms and disseminated disease with a palpable bulky liver. Imaging of NETs is therefore challenging and the imaging needs in the various patients are diverse. The basic modalities for NET imaging are computed tomography (CT) or magnetic resonance imaging (MRI) in combination with somatostatin receptor imaging (SMI) by scintigraphy with 111In-labelled octreotide (OctreoScan) or more recently by positron emission tomography (PET) with 68Ga-labelled somatostatin analogues. In this review these various morphological and functional imaging modalities and important methodological aspects are described. Imaging requirements for the various types of NETs are discussed and typical image findings are illustrated. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available